1 / 24

Endometrial Cancer

Endometrial Cancer. Tseng Jen-Yu 02/05/2007. Overview. Origin => Uterine endometrial lining Most common gynecologic malignancy 35,000 cases diagnosed each year Resulting in 4000 ~ 5000 deaths Normally occurs in postmenopausal Average age at diagnosis => 60 y/o < 5% under age of 40

Download Presentation

Endometrial Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Endometrial Cancer Tseng Jen-Yu 02/05/2007

  2. Overview • Origin => Uterine endometrial lining • Most common gynecologic malignancy • 35,000 cases diagnosed each year • Resulting in 4000 ~ 5000 deaths • Normally occurs in postmenopausal • Average age at diagnosis => 60 y/o • < 5% under age of 40 • Lifetime risk: 1.1% • Lifetime risk of dying: 0.4%

  3. Estrogen dependent disease • Prolonged exposure without the balancing effects of progesterone • Premalignant potential • Endometrial hyperplasia • Simple => 1% • Complex => 3% • Simple with atypia => 8% • Complex with atypia => 29%

  4. Incidence and Prevalence • Most common gynecologic cancer • 4th most common in women (US) • 2nd most common in women (UK) • 5th most common in women (worldwide) • Western developed > Southeast asia • 35,000 new cases annually • 5,000 death annually • Increase in the 1970’s • Increased use of menopausal estrogen therapy

  5. Types • 90% endometrial adenocarcinoma • Arise from the epithelium • Tumor grading • Grade 1 • Well differentiated • Grade 2 • Moderately differentiated with solid component • Grade 3 • Poorly differentiated with solid sheets of tumor

  6. 10% rare cell types • Papillary serous carcinoma • Clear cell carcinoma • Papillary endometrial carcinoma • Mucinous carcinoma • Rarer cancers • Onset at later age • Greater risk for metastases • Poorer prognosis • 50% of treatment failure

  7. Risk Factors • Obesity • Excess weight have 2 ~ 5 x greater risk • Fat cells (adipocytes) produce estrogen • Diabetes Mellitus and Hypertension • DM women have 2 x greater risk • Nulliparity • Progesterone counterbalances estrogen • Pregnancy lowers risk

  8. Early Menarche and Late Menopause • Associated with more estrogen exposure • Estrogen Replacement Therapy • Place women at high risk • Risk reduced when + progesterone • Tamoxifen • Anti-estrogenic drug for breast cancer • Side effect • Induces non-cancerous uterine tumors • Some may develop into endometrial cancer • Long term use => endometrial cancer • Only 1 in 500 develop endometrial cancer

  9. Genetic Predisposition • Risk may approach 50% in some families • Previous Cancer • History of breast / colon / ovarian cancer are at increased risk • Time interval can be as long as 10 years • Diet • Association is still unclear • Diet rich in animal fat and protein => risk ^ • Diet rich in vegetable, fruits, grain=> risk v

  10. Reduced Risk • Oral Contraceptives • Combined OC => 50% reduced rate • Actual reduction number small because uncommon in women of child bearing age • Long term offers protection • Reduced risk presumably => progesterone • Tobacco Smoking • Some evidence that it reduces the rate • Smokers have lower levels of estrogen and lower rate of obesity

  11. Prevention and Survival • Early detection is best prevention • Treating precancerous hyperplasia • Hormones (progestin) • D&C • Hysterectomy • 10 ~ 30% untreated develop into cancer • Average 5 year survival • Stage I => 72 ~ 90% • Stage II=> 56 ~ 60% • Stage III => 32 ~ 40% • Stage IV => 5 ~ 11%

  12. Signs • Postmenopausal vaginal bleeding • Abnormal uterine bleeding • Bleeding in between periods • Heavier / longer lasting menstrual bleeding • Abnormal vaginal discharge / Pyometra • Pelvic or back pain • Pain on urination • Pain on sexual intercourse • Blood in stool or urine

  13. Diagnosis • Endometrial sampling • Dilation and curettage / Endometrial aspiration • Image • TVS / CT scan / MRI • Standard • Hysteroscopy + targeted biopsy • Tumor marker • Ca 125 / 199 • Cystoscope / Proctoscope

  14. Staging • Stage I • Tumor confined to uterine body • Stage Ia • Tumor limited to endometrium • Stage Ib • Tumor invades less than ½ of myometrium • Stage Ic • Tumor invades more than ½ of myometrium • Stage II • Tumor extends to the cervix • Stage IIa • Cervical extension limited to endocervical glands • Stage IIb • Tumor invades cervical stroma

  15. Stage III • Regional tumor spread • Stage IIIa • Tumor invades serosa / adnexa / peritoneum / ascites (+) • Stage IIIb • Vaginal involvement / metastases present • Stage IIIc • Tumor spread to pelvic LN • Stage IV • Bulky pelvic disease or distant spread • Stage IVa • Tumor has spread to bladder or rectum • Stage IVb • Distant metastases present / inguinal LN

  16. Spread • Direct spread • Through endometrial cavity to the cervix • Through fallopian tubes to ovary / peritoneum • Invade myometrium reaching serosa • Rare: invasion to pubic bone • Lymphatic spread • Pelvic and para-aortic LN • Inguinal LN ( rare ) • Hematogenous spread • Rare but may spread to lungs

  17. Treatment • Surgery • Early stage ( I and II ) • Typical surgery is ATH + BSO + BPLND • VTH + BSO + laparoscopic BPLND • LAVH + BPLND • Advanced stage • Debulking surgery • Radiotherapy +/- hormone / chemotherapy

  18. Radiation • External beam pelvic radiation • Reserve use of radiotherapy until post-ATH • Adjuvant radiation therapy is controversial • Regional pelvic radiation proven to decrease pelvic recurrence • Not necessarily improve survival rate • Most beneficial for patients with tumor confined to the pelvis • Patients with increased likelihood of recurrence ( Stage Ic to IIIc) • Brachytherapy • Prevent vaginal cuff recurrence

  19. Hormonal therapy • Progesterone => for metastatic cancer • Less than 20% response rate • Chemotherapy • No clear results on effectiveness • Potentially most useful in metastatic cancer • Not as important as surgery and radiation • Only used in advanced or recurrent tumor after definitive treatment with surgery and radiation

  20. Recurrence • Likely in women with advanced disease • Within 3 years of original diagnosis • Hormone therapy can be considered • Use of chemotherapy is being evaluated • External beam pelvic radiation or brachytherapy

  21. Thank you for your attention

More Related